Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Intellia Therapeutics stock

NTLA
US45826J1051
A2AG6H

Price

14.87
Today +/-
+0.36
Today %
+2.56 %

Intellia Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Intellia Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Intellia Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Intellia Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Intellia Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Intellia Therapeutics Stock Price History

DateIntellia Therapeutics Price
12/5/202414.87 undefined
12/4/202414.49 undefined
12/3/202414.65 undefined
12/2/202415.73 undefined
11/29/202415.62 undefined
11/27/202415.22 undefined
11/26/202414.73 undefined
11/25/202414.79 undefined
11/22/202414.30 undefined
11/21/202413.80 undefined
11/20/202413.12 undefined
11/19/202414.13 undefined
11/18/202414.17 undefined
11/15/202413.97 undefined
11/14/202415.12 undefined
11/13/202416.98 undefined
11/12/202416.65 undefined
11/11/202417.50 undefined
11/8/202416.73 undefined
11/7/202416.00 undefined
11/6/202416.06 undefined

Intellia Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Intellia Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Intellia Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Intellia Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Intellia Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Intellia Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Intellia Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Intellia Therapeutics’s growth potential.

Intellia Therapeutics Revenue, EBIT and net profit per share

DateIntellia Therapeutics RevenueIntellia Therapeutics EBITIntellia Therapeutics Net Income
2029e3.31 B undefined1.49 B undefined1.86 B undefined
2028e1.69 B undefined456.35 M undefined719.87 M undefined
2027e644.68 M undefined-211.74 M undefined-5.99 M undefined
2026e63.29 M undefined-663.91 M undefined-578.11 M undefined
2025e54.67 M undefined-611.98 M undefined-569.78 M undefined
2024e55.47 M undefined-549.93 M undefined-552.34 M undefined
202336.28 M undefined-515.29 M undefined-481.19 M undefined
202252.12 M undefined-458.16 M undefined-474.19 M undefined
202133.05 M undefined-267.85 M undefined-267.89 M undefined
202057.99 M undefined-136.58 M undefined-134.23 M undefined
201943.1 M undefined-106.37 M undefined-99.53 M undefined
201830.43 M undefined-90.87 M undefined-85.34 M undefined
201726.12 M undefined-69.56 M undefined-67.54 M undefined
201616.48 M undefined-32.16 M undefined-31.63 M undefined
20156.04 M undefined-13.41 M undefined-12.4 M undefined
20140 undefined-3.48 M undefined-9.54 M undefined

Intellia Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00.010.020.030.030.040.060.030.050.040.060.050.060.641.693.31
--166.6762.5015.3843.3332.56-42.1157.58-30.7752.78-1.8216.67922.22162.5895.68
----------------
0000000000000000
-0.01-0.01-0.03-0.07-0.09-0.1-0.13-0.27-0.47-0.48-0.55-0.57-0.58-0.010.721.86
-33.33158.33116.1326.8716.4735.3599.2577.531.4814.763.081.58-99.13-14,480.00158.28
35.135.122.2236.0143.0747.2555.9970.8976.9788.77000000
----------------
Details

Keystats

ⓘ

Revenue and Growth

The Intellia Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Intellia Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
2014201520162017201820192020202120222023
                   
0.010.080.270.340.310.280.60.751.190.91
016.510.57.54.62.123.836.46
0000000000
0000000000
0.30.81.83.73.45.11718.620.449.65
0.010.080.280.350.330.290.620.771.221
0.32.710.615.317.137.155.1100.1161148.14
000004.70395.5101.8136.43
0000000000
0000000000
0000000000
0.31.876.15.32.94.729.640.518.08
0.64.517.621.422.444.759.8525.2303.3302.65
0.010.080.30.380.350.330.681.291.521.3
                   
17.188.600000000.01
000.260.420.480.570.961.752.422.71
-9.5-21.9-53.6-121.1-201-300.9-435.1-703-1,177.2-1,658.38
000003000-2,600-7,500-2,258
0000000000
0.010.070.210.30.280.270.531.041.241.05
0.21.44.72.22.73.910.59.75.27.45
2.22.85.9810.71931.352.477.685.62
06.520.221.227.112.722.563.843.822.14
0000000000
0000000000
2.410.730.831.440.535.664.3125.9126.6115.21
0000000000
0000000000
0.84.158.444.328.828.885128.4158135.6
0.84.158.444.328.828.885128.4158135.6
3.214.889.275.769.364.4149.3254.3284.6250.81
0.010.080.30.380.350.330.681.291.521.3
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Intellia Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Intellia Therapeutics's financial health and stability.

Assets

Intellia Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Intellia Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Intellia Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Intellia Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2014201520162017201820192020202120222023
-9-12-31-67-85-99-134-267-474-481
0012456678
0000000000
01059-163-2057-22-53-52
611330332640105278264
0000000000
0000000000
-2-136-65-61-103-49-225-333-394
0-2-6-10-6-6-3-12-13-13
0-2-6-10-26025-214-550160-31
0000-25431-210-538173-17
0000000000
0000000000
1271170142404371736582130
12701671424076371736582130
0-1-300720000
0000000000
96519767-281-1107-39409-295
-2.6-4.3129.94-75.37-67.62-110.03-53.5-237.79-346.85-408.07
0000000000

Intellia Therapeutics stock margins

The Intellia Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Intellia Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Intellia Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Intellia Therapeutics's sales revenue. A higher gross margin percentage indicates that the Intellia Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Intellia Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Intellia Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Intellia Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Intellia Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Intellia Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Intellia Therapeutics Margin History

Intellia Therapeutics Gross marginIntellia Therapeutics Profit marginIntellia Therapeutics EBIT marginIntellia Therapeutics Profit margin
2029e0 %45.06 %56.14 %
2028e0 %26.99 %42.57 %
2027e0 %-32.84 %-0.93 %
2026e0 %-1,048.97 %-913.4 %
2025e0 %-1,119.41 %-1,042.22 %
2024e0 %-991.5 %-995.84 %
20230 %-1,420.51 %-1,326.51 %
20220 %-879.05 %-909.8 %
20210 %-810.44 %-810.56 %
20200 %-235.52 %-231.47 %
20190 %-246.8 %-230.93 %
20180 %-298.62 %-280.45 %
20170 %-266.31 %-258.58 %
20160 %-195.15 %-191.93 %
20150 %-222.02 %-205.3 %
20140 %0 %0 %

Intellia Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Intellia Therapeutics earnings per share therefore indicates how much revenue Intellia Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Intellia Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Intellia Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Intellia Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Intellia Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Intellia Therapeutics Revenue, EBIT and net profit per share

DateIntellia Therapeutics Sales per ShareIntellia Therapeutics EBIT per shareIntellia Therapeutics Earnings per Share
2029e32.58 undefined0 undefined18.29 undefined
2028e16.65 undefined0 undefined7.09 undefined
2027e6.35 undefined0 undefined-0.06 undefined
2026e0.62 undefined0 undefined-5.69 undefined
2025e0.54 undefined0 undefined-5.61 undefined
2024e0.55 undefined0 undefined-5.44 undefined
20230.41 undefined-5.8 undefined-5.42 undefined
20220.68 undefined-5.95 undefined-6.16 undefined
20210.47 undefined-3.78 undefined-3.78 undefined
20201.04 undefined-2.44 undefined-2.4 undefined
20190.91 undefined-2.25 undefined-2.11 undefined
20180.71 undefined-2.11 undefined-1.98 undefined
20170.73 undefined-1.93 undefined-1.88 undefined
20160.74 undefined-1.45 undefined-1.42 undefined
20150.17 undefined-0.38 undefined-0.35 undefined
20140 undefined-0.1 undefined-0.27 undefined

Intellia Therapeutics business model

Intellia Therapeutics Inc is a leading biotechnology company specializing in the development of therapeutic solutions based on CRISPR/Cas9 technologies. It was founded in May 2014 and is headquartered in Cambridge, Massachusetts, USA. The company is listed on NASDAQ under the ticker symbol NTLA. Intellia Therapeutics is one of the most popular companies on Eulerpool.com.

Intellia Therapeutics SWOT Analysis

Strengths

Intellia Therapeutics Inc has a strong intellectual property portfolio consisting of patents and licenses, providing them with a competitive advantage in gene editing technologies.

The company has a diverse pipeline of potential therapeutics, covering various diseases and conditions, which helps in reducing dependency on single product success.

Intellia Therapeutics has formed strategic partnerships and collaborations with leading pharmaceutical companies, allowing them to benefit from shared resources, expertise, and strong distribution networks.

Weaknesses

Being a relatively small biotechnology company, Intellia Therapeutics Inc may face financial limitations and struggle to compete against larger, well-established competitors in terms of resources and market presence.

The company's success heavily relies on the successful development and approval of its pipeline products. Any setbacks or delays in clinical trials or regulatory processes could negatively impact the company.

As a gene editing company, Intellia Therapeutics is subject to ethical and regulatory concerns surrounding the use of gene therapies, which can limit market adoption and public acceptance.

Opportunities

The increasing prevalence of genetic disorders and chronic diseases presents a significant opportunity for Intellia Therapeutics to develop and commercialize innovative gene therapies that can address unmet medical needs.

Advancements in gene editing technologies and the growing understanding of genetic mechanisms provide Intellia Therapeutics with the opportunity to enhance the efficacy and safety of their therapies, potentially leading to greater market adoption.

Expanding into emerging markets and forming partnerships with international pharmaceutical companies can facilitate global market penetration for Intellia Therapeutics and increase their revenue streams.

Threats

Intense competition within the gene editing industry poses a threat to Intellia Therapeutics' market share and profitability, as larger players with more resources may develop similar or superior therapies.

Regulatory hurdles and evolving government policies related to gene editing and healthcare reimbursement can impact the speed of product approvals and the pricing and reimbursement of Intellia Therapeutics' therapies.

Unforeseen adverse events, such as unexpected side effects or lack of long-term safety data, in Intellia Therapeutics' clinical trials or approved products can lead to reputational damage and loss of investor confidence.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Intellia Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Intellia Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Intellia Therapeutics shares outstanding

The number of shares was Intellia Therapeutics in 2023 — This indicates how many shares 88.77 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Intellia Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Intellia Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Intellia Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Intellia Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Intellia Therapeutics.

Intellia Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-1.41 -1.34  (5.12 %)2024 Q3
6/30/2024-1.26 -1.52  (-20.94 %)2024 Q2
3/31/2024-1.41 -1.12  (20.4 %)2024 Q1
12/31/2023-1.48 -1.46  (1.22 %)2023 Q4
9/30/2023-1.53 -1.38  (9.73 %)2023 Q3
6/30/2023-1.35 -1.4  (-3.91 %)2023 Q2
3/31/2023-1.43 -1.17  (18.08 %)2023 Q1
12/31/2022-1.42 -1.4  (1.45 %)2022 Q4
9/30/2022-1.31 -1.49  (-13.96 %)2022 Q3
6/30/2022-1.33 -1.33  (0.17 %)2022 Q2
1
2
3
4

Eulerpool ESG Scorecard© for the Intellia Therapeutics stock

Eulerpool World ESG Rating (EESG©)

58/ 100

🌱 Environment

36

👫 Social

77

🏛️ Governance

62

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees56
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Intellia Therapeutics shareholders

%
Name
Stocks
Change
Date
11.41543 % ARK Investment Management LLC11,595,789606,5076/30/2024
8.93618 % The Vanguard Group, Inc.9,077,3701,9326/30/2024
7.72284 % BlackRock Institutional Trust Company, N.A.7,844,864301,6016/30/2024
4.72534 % Deep Track Capital LP4,800,000589,2166/30/2024
4.29492 % State Street Global Advisors (US)4,362,780-235,0426/30/2024
3.20702 % Nikko Asset Management Co., Ltd.3,257,689-141,6296/30/2024
2.25826 % Geode Capital Management, L.L.C.2,293,943249,6866/30/2024
2.24389 % Federated Hermes Global Investment Management Corp.2,279,340349,6406/30/2024
2.00837 % Fidelity Management & Research Company LLC2,040,10125,0566/30/2024
1.96889 % Casdin Capital, LLC2,000,000125,0006/30/2024
1
2
3
4
5
...
10

Intellia Therapeutics Executives and Management Board

Dr. John Leonard

(65)
Intellia Therapeutics President, Chief Executive Officer, Director (since 2014)
Compensation 10.1 M

Mr. Derek Hicks

(50)
Intellia Therapeutics Executive Vice President, chief business officer
Compensation 5.08 M

Dr. David Lebwohl

(67)
Intellia Therapeutics Executive Vice President, Chief Medical Officer
Compensation 3.72 M

Dr. Laura Sepp-Lorenzino

(62)
Intellia Therapeutics Executive Vice President, Chief Scientific Officer
Compensation 3.72 M

Mr. James Basta

(57)
Intellia Therapeutics Executive Vice President, General Counsel, Corporate Secretary
Compensation 3.63 M
1
2
3

Most common questions regarding Intellia Therapeutics

What values and corporate philosophy does Intellia Therapeutics represent?

Intellia Therapeutics Inc is a leading biotechnology company that focuses on developing CRISPR/Cas9 genome editing technology. The company's corporate philosophy revolves around innovation, collaboration, and scientific excellence. Intellia Therapeutics is committed to revolutionizing medicine by utilizing CRISPR/Cas9 to potentially treat various genetic diseases. With a mission to develop curative therapeutics, Intellia Therapeutics aims to transform the lives of patients and their families. The company values integrity, diversity, and dedication to science-driven advancements. Through its cutting-edge research and passionate team, Intellia Therapeutics is committed to delivering groundbreaking solutions and making a lasting impact in the field of gene editing.

In which countries and regions is Intellia Therapeutics primarily present?

Intellia Therapeutics Inc primarily operates in the United States.

What significant milestones has the company Intellia Therapeutics achieved?

Intellia Therapeutics Inc has achieved several significant milestones. Notably, the company successfully entered into a collaboration with Novartis to develop and commercialize CAR-T cell therapies utilizing its CRISPR/Cas9 technology. Additionally, Intellia Therapeutics became the first company to demonstrate in vivo editing using CRISPR/Cas9 in a non-human primate model. Furthermore, the company received FDA clearance for its Investigational New Drug (IND) application for the treatment of transthyretin amyloidosis, which marked a crucial step in developing potential therapies for this rare disease. Intellia Therapeutics continues to make progress in leveraging its innovative gene editing platform to pave the way for novel therapeutic interventions.

What is the history and background of the company Intellia Therapeutics?

Intellia Therapeutics Inc is a biotechnology company based in Cambridge, Massachusetts. Founded in 2014, Intellia is focused on developing CRISPR/Cas9 genome editing technology for therapeutic applications. The company aims to revolutionize medicine by harnessing the power of CRISPR to eradicate genetic diseases, create more effective and precise treatments, and improve patient outcomes. Intellia has pioneered several groundbreaking research initiatives and strategic collaborations, including partnerships with leading pharmaceutical companies. With a strong commitment to innovation and scientific excellence, Intellia Therapeutics Inc continues to make significant strides in advancing the field of gene editing and unlocking potential cures for debilitating genetic disorders.

Who are the main competitors of Intellia Therapeutics in the market?

The main competitors of Intellia Therapeutics Inc in the market include CRISPR Therapeutics AG, Editas Medicine Inc, and Sangamo Therapeutics Inc.

In which industries is Intellia Therapeutics primarily active?

Intellia Therapeutics Inc is primarily active in the biotechnology industry.

What is the business model of Intellia Therapeutics?

Intellia Therapeutics Inc. is a leading biotechnology company specializing in the development of potentially curative medicines based on CRISPR/Cas9 gene editing technology. The company's business model revolves around using this innovative gene editing platform to develop and commercialize novel therapies for a wide range of genetic diseases. Intellia Therapeutics aims to leverage its expertise in genome editing to provide transformative treatments that address patients' unmet medical needs. By harnessing the power of CRISPR/Cas9, Intellia Therapeutics aims to revolutionize the biotechnology industry and make significant advancements in precision medicine.

What is the P/E ratio of Intellia Therapeutics 2024?

The Intellia Therapeutics P/E ratio is -2.39.

What is the P/S ratio of Intellia Therapeutics 2024?

The Intellia Therapeutics P/S ratio is 23.79.

What is the Quality Investing of Intellia Therapeutics?

The Quality Investing for Intellia Therapeutics is 3/10.

What is the revenue of Intellia Therapeutics 2024?

The expected Intellia Therapeutics revenue is 55.47 M USD.

How high is the profit of Intellia Therapeutics 2024?

The expected Intellia Therapeutics profit is -552.34 M USD.

What is the business model of Intellia Therapeutics

Intellia Therapeutics Inc is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapies for genetic diseases. The company utilizes CRISPR/Cas9 gene editing technology to make targeted changes in the human genome and potentially develop life-changing therapies. Intellia is currently focusing on the treatment of liver diseases such as hereditary transthyretin amyloidosis (ATTR) and hemophilia, which is based on a malfunction of the blood clotting system. The company is also dedicated to developing therapies for cancer and rare genetic diseases. Intellia's main products are genetic therapies that aim to remove or repair disease-causing mutations in patients' genomes. These therapies utilize CRISPR/Cas9 gene editing technology to cut and efficiently edit DNA. The company has also formed partnerships with other biotechnology and pharmaceutical companies to apply this technology to other areas of medicine and research. Intellia has a pipeline of therapies in various stages of development. The company collaborates closely with academics and industry experts to explore and expand the technology and the benefits of clinical medical studies and more precise diagnostic procedures. Intellia's business strategy is to bring significant therapeutic innovations to market by leveraging its expertise in CRISPR/Cas9 technology. The company has a strong financial position that allows it to invest in the development of innovative therapies and technologies. It has also formed strategic partnerships with companies such as Regeneron Pharmaceuticals and Novartis to accelerate research and development. Intellia believes that its technology has the potential to revolutionize the treatment of diseases and create immense opportunities for scientists, patients, and investors over time. The company is committed to utilizing CRISPR/Cas9 technology to develop groundbreaking therapies that improve patients' lives and advance medical research.

What is the Intellia Therapeutics dividend?

Intellia Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Intellia Therapeutics pay dividends?

The dividend cannot currently be calculated for Intellia Therapeutics or the company does not pay out a dividend.

What is the Intellia Therapeutics ISIN?

The ISIN of Intellia Therapeutics is US45826J1051.

What is the Intellia Therapeutics WKN?

The WKN of Intellia Therapeutics is A2AG6H.

What is the Intellia Therapeutics ticker?

The ticker of Intellia Therapeutics is NTLA.

How much dividend does Intellia Therapeutics pay?

Over the past 12 months, Intellia Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Intellia Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Intellia Therapeutics?

The current dividend yield of Intellia Therapeutics is .

When does Intellia Therapeutics pay dividends?

Intellia Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Intellia Therapeutics?

Intellia Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Intellia Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Intellia Therapeutics located?

Intellia Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Intellia Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Intellia Therapeutics from 12/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/5/2024.

When did Intellia Therapeutics pay the last dividend?

The last dividend was paid out on 12/5/2024.

What was the dividend of Intellia Therapeutics in the year 2023?

In the year 2023, Intellia Therapeutics distributed 0 USD as dividends.

In which currency does Intellia Therapeutics pay out the dividend?

The dividends of Intellia Therapeutics are distributed in USD.

All fundamentals about Intellia Therapeutics

Our stock analysis for Intellia Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Intellia Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.